MedX Health Corp. Increases International Footprint -- Major Milestone in Turkey

MISSISSAUGA, ON--(Marketwired - March 31, 2016) - MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX), a leading medical device company, MedX Health Corp. announced today that it has received Ministry of Health official registration in Turkey, allowing MedX to sell its SIAscopy based skin assessment systems into this large market.

"Turkey has a population of just under 80 million, it has benefited from significant health care reform, including universal health care, and is a country with increasing incidence of skin cancer; for these reasons MedX established a Representative Office there in 2015," explained Robert von der Porten, CEO.

Through the efforts of its representative, SIAscopy demonstration systems were deployed in IUH, the leading dermatology center in Turkey. MedX's products appeared on Turkish TV http://siascopyturkey.com/default.aspx, and have been exhibited at the Istanbul Bakırkoy municipality CeBit trade show where Dr Zekeyi Kutlubay, a leading dermatologist was the keynote speaker for "Skin Cancer and the Importance of Early Diagnosis."

"I can cordially say that SIAscopy is the best nevus assessment and diagnosis device available," stated Dr. Zekayi Kutlubay, Associate Professor of Dermatology at the Istanbul University Cerrahpasa Medical Faculty Department of Dermatology. "With SIAscopy, it is possible to obtain more quality dermatoscopic images of a nevus and assess its structural features inside the skin; you will make better assessments and therefore have better patient outcomes. In my humble opinion, each Dermatologist should have a Siascopy as part of their practice."

"Endorsements like this should have a very positive impact in building initial SIAscopy sales in Turkey," continued Mr. von der Porten, "we also believe that we will continue to benefit from increasing sales momentum there."

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer; it manufactures and distributes SIMSYS™ and MoleMate™, hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in drugstore settings where the images are sent remotely to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.